Other Research Publications

Blood mRNA Measurement (NETest) for Neuroendocrine Tumor Diagnosis of Image-Negative Liver Metastatic Disease

The Endocrine Society has accepted the NETest as a biomarker for microscopic liver disease (minimal residual disease) in neuroendocrine tumors for their thematic issue on Neuroendocrinology in 2019.

The data identifies that “Emerging molecular liquid biopsies (e.g., NETest) provide a substantially improved threshold for disease detection.” 

Click here to read the full article

How Does Prognosis of NETs Differ Based on Site of Origin? by Dave Levitan

An analysis of more than 70,000 patients revealed significant differences with regard to survival between different sites of origin for neuroendocrine tumors (NETs). These differences could help guide therapy in these malignancies.

Click here to read the full article

From Patent to Patient 

Analysing access to innovative cancer drugs. 

The Institute of Cancer Research (ICR) have produced a report which asks how we can best harness advances in science to bring innovative drugs to patients. It is designed to help reshape the landscape for drug discovery and development – and create tomorrow’s cancer treatments.

Click here to read the full report

Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas

This review covers the diverse topic of neuroendocrine neoplasms ( NENs).

Click here to read the full report

The Colorful Palette of Neuroendocrine Neoplasms in the Genitourinary Tract

A review of  the  rare NENs of the genitourinary tract. 

Click here to read the full report

Liver Transplantation in patients with liver metastases from neuroendocrine tumors – A Systematic Review

A controversial topic with no clear answers yet, but a very strict selection process is key.

Click here to read the full report

Editorial for Neuroendocrine Tumor for Liver Transplant

Still a rare indication for liver transplantation. The efficacy of this treatment for NETs is unproven.

Click here to read the full report

OBLIQUE LUNA | UK PI John Ramage

Observational study to assess quality of life in patients with pancreatic neuroendocrine tumours receiving treatment with Everolimus: The OBLIQUE Study (UK Phase IV trial). Ramage JK, Punia P, Faluyi O, Frilling A, Meyer T, Saharan R, Valle JW. Neuroendocrinology. 2019 Jan 30

Click here to read the full report

LUNA | UK PI Tim Meyer [NCRN574] Published  

Ferolla P, Brizzi MP, Meyer T, Mansoor W, Mazieres J, Do Cao C, Léna H, Berruti A, Damiano V, Buikhuisen W, Grønbæk H, Lombard-Bohas C, Grohé C, Minotti V, Tiseo M, De Castro J, Reed N, Gislimberti G, Singh N, Stankovic M, Öberg K, Baudin E. Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol. 2017 Dec;18(12):1652-1664

Click here to read the full report

BEZ235-F2201 | UK PI Nick Reed  [NCRN 12919] Published 

Salazar R, Garcia-Carbonero R, Libutti SK, Hendifar AE, Custodio A, Guimbaud R, Lombard-Bohas C, Ricci S, Klümpen HJ, Capdevila J, Reed N, Walenkamp A, Grande E, Safina S, Meyer T, Kong O, Salomon H, Tavorath R, Yao JC.  Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Naïve Advanced Pancreatic Neuroendocrine Tumors. The Oncologist. 2017 Dec doi: 10.1634/theoncologist.2017-0144

Click here to read the full report

COOPERATE-2 | UK PI Juan Valle [NCRN239] Published

Kulke MH, Ruszniewski P, Van Cutsem E, Lombard-Bohas C, Valle JW, De Herder WW, Pavel M, Degtyarev E, Brase JC, Bubuteishvili-Pacaud L, Voi M, Salazar R, Borbath I, Fazio N, Smith D, Capdevila J, Riechelmann RP, Yao JC. A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial. Ann Oncol. 2017 Jun 1;28(6):1309-1315.

Click here to read the full report

RADIANT-4 | UK PI Juan Valle [NCRN333] Published 

Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, Tomasek J, Raderer M, Lahner H, Voi M, Pacaud LB, Rouyrre N, Sachs C, Valle JW, Fave GD, Van Cutsem E, Tesselaar M, Shimada Y, Oh DY, Strosberg J, Kulke MH, Pavel ME; RAD001 in Advanced Neuroendocrine Tumours, Fourth Trial (RADIANT-4) Study Group. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2016 Mar 5;387(10022):968-977

Click here to read the full report

NETTER-1 | UK PI Ashley Grossman [NCRN328] Published

Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H, Bushnell D, O’Dorisio TM, Baum RP, Kulkarni HR, Caplin M, Lebtahi R, Hobday T, Delpassand E, Van Cutsem E, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Öberg K, Lopera Sierra M, Santoro P, Thevenet T, Erion JL, Ruszniewski P, Kwekkeboom D, Krenning E; NETTER-1 Trial InvestigatorsPhase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017 Jan 12;376(2):125-135.

Click here to read the full report

TELESTAR | UK PI Martyn Caplin [NCRN502] Published 

Kulke MH, Hörsch D, Caplin ME, Anthony LB, Bergsland E, Öberg K, Welin S, Warner RR, Lombard-Bohas C, Kunz PL, Grande E, Valle JW, Fleming D, Lapuerta P, Banks P, Jackson S, Zambrowicz B, Sands AT, Pavel M. Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome. J Clin Oncol. 2017 Jan;35(1):14-23

Click here to read the full report